Bio-Path Holdings (NASDAQ: BPTH) is a clinical stage biotechnology company developing therapeutics for the treatment of cancer and systemic diseases. Bio-Path's RNAi technology for drug development, DNAbilize™, uses a novel liposomal antisense DNA platform that allows for systemic delivery of nucleic acids without toxicity. Using DNAbilize™ clinicians can inhibit the production of proteins involved in cancer and block pathways involved in disease progression.  
 

COMPANY HIGHLIGHTS

• Proprietary antisense and liposome delivery technology breakthrough for DNA drugs, potentially solving the challenges of delivering these molecules directly to target cells without side effects
• Original technology licensed from The MD Anderson Cancer Center. Company maintains strong relationship with the Cancer Center
• Strong IP position with composition of matter and method patents for antisense targets and manufacturing
• Lead product candidate, prexigebersen (Liposomal Grb2) formerly BP1001, in the clinic for blood cancers and in development for solid tumors. Second product candidate, BP1002 (Liposomal Bcl2) is IND-ready
• Promising clinical data for BP1001 shows that the drug has been well tolerated with possible anti-leukemic effects, including patients stabilizing for extended treatment

Learn More

Bio-Path Holdings (NASDAQ: BPTH) is a clinical stage biotechnology company developing therapeutics for the treatment of cancer and systemic diseases. Bio-Path's RNAi technology for drug development, DNAbilize™, uses a novel liposomal antisense DNA platform that allows for systemic delivery of nucleic acids without toxicity. Using DNAbilize™ clinicians can inhibit the production of proteins involved in cancer and block pathways involved in disease progression.  
 

COMPANY HIGHLIGHTS

• Proprietary antisense and liposome delivery technology breakthrough for DNA drugs, potentially solving the challenges of delivering these molecules directly to target cells without side effects
• Original technology licensed from The MD Anderson Cancer Center. Company maintains strong relationship with the Cancer Center
• Strong IP position with composition of matter and method patents for antisense targets and manufacturing
• Lead product candidate, prexigebersen (Liposomal Grb2) formerly BP1001, in the clinic for blood cancers and in development for solid tumors. Second product candidate, BP1002 (Liposomal Bcl2) is IND-ready
• Promising clinical data for BP1001 shows that the drug has been well tolerated with possible anti-leukemic effects, including patients stabilizing for extended treatment

Learn More

Bio-Path Holdings (NASDAQ: BPTH) is a clinical stage biotechnology company developing therapeutics for the treatment of cancer and systemic diseases. Bio-Path's RNAi technology for drug development, DNAbilize™, uses a novel liposomal antisense DNA platform that allows for systemic delivery of nucleic acids without toxicity. Using DNAbilize™ clinicians can inhibit the production of proteins involved in cancer and block pathways involved in disease progression.  
 

COMPANY HIGHLIGHTS

• Proprietary antisense and liposome delivery technology breakthrough for DNA drugs, potentially solving the challenges of delivering these molecules directly to target cells without side effects
• Original technology licensed from The MD Anderson Cancer Center. Company maintains strong relationship with the Cancer Center
• Strong IP position with composition of matter and method patents for antisense targets and manufacturing
• Lead product candidate, prexigebersen (Liposomal Grb2) formerly BP1001, in the clinic for blood cancers and in development for solid tumors. Second product candidate, BP1002 (Liposomal Bcl2) is IND-ready
• Promising clinical data for BP1001 shows that the drug has been well tolerated with possible anti-leukemic effects, including patients stabilizing for extended treatment

Learn More

Bio-Path Holdings (NASDAQ: BPTH) is a clinical stage biotechnology company developing therapeutics for the treatment of cancer and systemic diseases. Bio-Path's RNAi technology for drug development, DNAbilize™, uses a novel liposomal antisense DNA platform that allows for systemic delivery of nucleic acids without toxicity. Using DNAbilize™ clinicians can inhibit the production of proteins involved in cancer and block pathways involved in disease progression.  
 

COMPANY HIGHLIGHTS

• Proprietary antisense and liposome delivery technology breakthrough for DNA drugs, potentially solving the challenges of delivering these molecules directly to target cells without side effects
• Original technology licensed from The MD Anderson Cancer Center. Company maintains strong relationship with the Cancer Center
• Strong IP position with composition of matter and method patents for antisense targets and manufacturing
• Lead product candidate, prexigebersen (Liposomal Grb2) formerly BP1001, in the clinic for blood cancers and in development for solid tumors. Second product candidate, BP1002 (Liposomal Bcl2) is IND-ready
• Promising clinical data for BP1001 shows that the drug has been well tolerated with possible anti-leukemic effects, including patients stabilizing for extended treatment

Learn More

Bio-Path Holdings (NASDAQ: BPTH) is a clinical stage biotechnology company developing therapeutics for the treatment of cancer and systemic diseases. Bio-Path's RNAi technology for drug development, DNAbilize™, uses a novel liposomal antisense DNA platform that allows for systemic delivery of nucleic acids without toxicity. Using DNAbilize™ clinicians can inhibit the production of proteins involved in cancer and block pathways involved in disease progression.  
 

COMPANY HIGHLIGHTS

• Proprietary antisense and liposome delivery technology breakthrough for DNA drugs, potentially solving the challenges of delivering these molecules directly to target cells without side effects
• Original technology licensed from The MD Anderson Cancer Center. Company maintains strong relationship with the Cancer Center
• Strong IP position with composition of matter and method patents for antisense targets and manufacturing
• Lead product candidate, prexigebersen (Liposomal Grb2) formerly BP1001, in the clinic for blood cancers and in development for solid tumors. Second product candidate, BP1002 (Liposomal Bcl2) is IND-ready
• Promising clinical data for BP1001 shows that the drug has been well tolerated with possible anti-leukemic effects, including patients stabilizing for extended treatment

Learn More

Bio-Path Holdings (NASDAQ: BPTH) is a clinical stage biotechnology company developing therapeutics for the treatment of cancer and systemic diseases. Bio-Path's RNAi technology for drug development, DNAbilize™, uses a novel liposomal antisense DNA platform that allows for systemic delivery of nucleic acids without toxicity. Using DNAbilize™ clinicians can inhibit the production of proteins involved in cancer and block pathways involved in disease progression.  
 

COMPANY HIGHLIGHTS

• Proprietary antisense and liposome delivery technology breakthrough for DNA drugs, potentially solving the challenges of delivering these molecules directly to target cells without side effects
• Original technology licensed from The MD Anderson Cancer Center. Company maintains strong relationship with the Cancer Center
• Strong IP position with composition of matter and method patents for antisense targets and manufacturing
• Lead product candidate, prexigebersen (Liposomal Grb2) formerly BP1001, in the clinic for blood cancers and in development for solid tumors. Second product candidate, BP1002 (Liposomal Bcl2) is IND-ready
• Promising clinical data for BP1001 shows that the drug has been well tolerated with possible anti-leukemic effects, including patients stabilizing for extended treatment

Learn More

Bio-Path Holdings (NASDAQ: BPTH) is a clinical stage biotechnology company developing therapeutics for the treatment of cancer and systemic diseases. Bio-Path's RNAi technology for drug development, DNAbilize™, uses a novel liposomal antisense DNA platform that allows for systemic delivery of nucleic acids without toxicity. Using DNAbilize™ clinicians can inhibit the production of proteins involved in cancer and block pathways involved in disease progression.  
 

COMPANY HIGHLIGHTS

• Proprietary antisense and liposome delivery technology breakthrough for DNA drugs, potentially solving the challenges of delivering these molecules directly to target cells without side effects
• Original technology licensed from The MD Anderson Cancer Center. Company maintains strong relationship with the Cancer Center
• Strong IP position with composition of matter and method patents for antisense targets and manufacturing
• Lead product candidate, prexigebersen (Liposomal Grb2) formerly BP1001, in the clinic for blood cancers and in development for solid tumors. Second product candidate, BP1002 (Liposomal Bcl2) is IND-ready
• Promising clinical data for BP1001 shows that the drug has been well tolerated with possible anti-leukemic effects, including patients stabilizing for extended treatment

Learn More

Bio-Path Holdings (NASDAQ: BPTH) is a clinical stage biotechnology company developing therapeutics for the treatment of cancer and systemic diseases. Bio-Path's RNAi technology for drug development, DNAbilize™, uses a novel liposomal antisense DNA platform that allows for systemic delivery of nucleic acids without toxicity. Using DNAbilize™ clinicians can inhibit the production of proteins involved in cancer and block pathways involved in disease progression.  
 

COMPANY HIGHLIGHTS

• Proprietary antisense and liposome delivery technology breakthrough for DNA drugs, potentially solving the challenges of delivering these molecules directly to target cells without side effects
• Original technology licensed from The MD Anderson Cancer Center. Company maintains strong relationship with the Cancer Center
• Strong IP position with composition of matter and method patents for antisense targets and manufacturing
• Lead product candidate, prexigebersen (Liposomal Grb2) formerly BP1001, in the clinic for blood cancers and in development for solid tumors. Second product candidate, BP1002 (Liposomal Bcl2) is IND-ready
• Promising clinical data for BP1001 shows that the drug has been well tolerated with possible anti-leukemic effects, including patients stabilizing for extended treatment

Learn More

Bio-Path Holdings (NASDAQ: BPTH) is a clinical stage biotechnology company developing therapeutics for the treatment of cancer and systemic diseases. Bio-Path's RNAi technology for drug development, DNAbilize™, uses a novel liposomal antisense DNA platform that allows for systemic delivery of nucleic acids without toxicity. Using DNAbilize™ clinicians can inhibit the production of proteins involved in cancer and block pathways involved in disease progression.  
 

COMPANY HIGHLIGHTS

• Proprietary antisense and liposome delivery technology breakthrough for DNA drugs, potentially solving the challenges of delivering these molecules directly to target cells without side effects
• Original technology licensed from The MD Anderson Cancer Center. Company maintains strong relationship with the Cancer Center
• Strong IP position with composition of matter and method patents for antisense targets and manufacturing
• Lead product candidate, prexigebersen (Liposomal Grb2) formerly BP1001, in the clinic for blood cancers and in development for solid tumors. Second product candidate, BP1002 (Liposomal Bcl2) is IND-ready
• Promising clinical data for BP1001 shows that the drug has been well tolerated with possible anti-leukemic effects, including patients stabilizing for extended treatment

Learn More

Bio-Path Holdings (NASDAQ: BPTH) is a clinical stage biotechnology company developing therapeutics for the treatment of cancer and systemic diseases. Bio-Path's RNAi technology for drug development, DNAbilize™, uses a novel liposomal antisense DNA platform that allows for systemic delivery of nucleic acids without toxicity. Using DNAbilize™ clinicians can inhibit the production of proteins involved in cancer and block pathways involved in disease progression.  
 

COMPANY HIGHLIGHTS

• Proprietary antisense and liposome delivery technology breakthrough for DNA drugs, potentially solving the challenges of delivering these molecules directly to target cells without side effects
• Original technology licensed from The MD Anderson Cancer Center. Company maintains strong relationship with the Cancer Center
• Strong IP position with composition of matter and method patents for antisense targets and manufacturing
• Lead product candidate, prexigebersen (Liposomal Grb2) formerly BP1001, in the clinic for blood cancers and in development for solid tumors. Second product candidate, BP1002 (Liposomal Bcl2) is IND-ready
• Promising clinical data for BP1001 shows that the drug has been well tolerated with possible anti-leukemic effects, including patients stabilizing for extended treatment

Learn More

Bio-Path Holdings (NASDAQ: BPTH) is a clinical stage biotechnology company developing therapeutics for the treatment of cancer and systemic diseases. Bio-Path's RNAi technology for drug development, DNAbilize™, uses a novel liposomal antisense DNA platform that allows for systemic delivery of nucleic acids without toxicity. Using DNAbilize™ clinicians can inhibit the production of proteins involved in cancer and block pathways involved in disease progression.  
 

COMPANY HIGHLIGHTS

• Proprietary antisense and liposome delivery technology breakthrough for DNA drugs, potentially solving the challenges of delivering these molecules directly to target cells without side effects
• Original technology licensed from The MD Anderson Cancer Center. Company maintains strong relationship with the Cancer Center
• Strong IP position with composition of matter and method patents for antisense targets and manufacturing
• Lead product candidate, prexigebersen (Liposomal Grb2) formerly BP1001, in the clinic for blood cancers and in development for solid tumors. Second product candidate, BP1002 (Liposomal Bcl2) is IND-ready
• Promising clinical data for BP1001 shows that the drug has been well tolerated with possible anti-leukemic effects, including patients stabilizing for extended treatment

Learn More